Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
Department of Hematology, Mayo Clinic, Rochester, Minnesota.
Respir Care. 2023 Oct;68(10):1406-1416. doi: 10.4187/respcare.10925. Epub 2023 May 30.
Pulmonary function test (PFT) impairments are common after allogeneic hematopoietic stem cell transplantation. The prognostic significance of these declines on outcomes is not well understood.The objectives were to determine the frequency of declines in pulmonary function (FVC, FEV, and diffusing capacity for carbon monoxide [D]) in the early post-transplantation period; and to determine the prognostic significance of these declines on mortality or development of bronchiolitis obliterans syndrome.
This was a retrospective cohort study conducted at Mayo Clinic, Rochester, Minnesota. PFTs were obtained at baseline and at day +100. Competing risk survival models were developed, which accounted for pre-transplantation pulmonary function and relapse status.
Between January 1, 2005, and December 31, 2020, 1,145 subjects underwent allogeneic hematopoietic stem cell transplantation and had a pre-transplantation PFT performed. Of these, 900 (78.6%) survived to day 100 and had post-transplantation PFTs performed (median [interquartile range] 97 [94-103] d). A decline of ≥10% in FEV FVC, or D was seen in 401 of 900 subjects (44.5%). Declines of ≥20% in FEV (hazard ratio 1.65, 95% CI 1.07-2.56; = .02), FVC (hazard ratio 1.72, 95% CI [1.11-2.67]; = .02), and D (hazard ratio 1.46, 95% CI 1.04-2.07; = .028) were all associated with reduced survival when compared with those with < 10% decline in PFT measures. These findings were independent of pre-transplantation pulmonary function or relapse status. Bronchiolitis obliterans syndrome was diagnosed in 118 subjects (10.3%), and there was no relationship between early PFT decline and a subsequent diagnosis of bronchiolitis obliterans syndrome. The subjects who received myeloablative conditioning with cyclophosphamide plus total body irradiation or cyclophosphamide plus fludarabine plus total body irradiation were more likely to have lower spirometry values after hematopoietic stem cell transplantation. The subjects who received reduced intensity conditioning or nonmyeloablative conditioning with fludarabine plus total body irradiation were more likely to have higher post-hematopoietic stem cell transplantation FEV, FVC, and D.
An absolute decline of ≥20% in FEV, FVC, or D were associated with reduced survival independent of pre-transplantation pulmonary function or relapse status. In contrast to previous work, early declines in PFT measures were not associated with future development of bronchiolitis obliterans syndrome.
异基因造血干细胞移植后常出现肺功能测试(PFT)损伤。这些下降对结局的预后意义尚不清楚。目的是确定在移植后早期肺功能(FVC、FEV 和一氧化碳弥散量[D])下降的频率;并确定这些下降对死亡率或闭塞性细支气管炎综合征发展的预后意义。
这是明尼苏达州罗切斯特市梅奥诊所进行的一项回顾性队列研究。在基线和+100 天时获得 PFT。建立了竞争风险生存模型,该模型考虑了移植前的肺功能和复发状态。
2005 年 1 月 1 日至 2020 年 12 月 31 日,1145 名患者接受了异基因造血干细胞移植,并进行了移植前 PFT。其中,900 名(78.6%)存活至 100 天并进行了移植后 PFT(中位数[四分位距]97 [94-103] d)。900 名患者中有 401 名(44.5%)出现 FEV、FVC 或 D 下降≥10%。与 PFT 测量值下降<10%的患者相比,FEV 下降≥20%(风险比 1.65,95%CI [1.07-2.56]; =.02)、FVC(风险比 1.72,95%CI [1.11-2.67]; =.02)和 D(风险比 1.46,95%CI [1.04-2.07]; =.028)的下降均与生存降低相关。这些发现与移植前的肺功能或复发状态无关。118 名患者(10.3%)诊断为闭塞性细支气管炎综合征,早期 PFT 下降与随后诊断为闭塞性细支气管炎综合征之间无相关性。接受环磷酰胺加全身照射或环磷酰胺加氟达拉滨加全身照射的清髓性预处理的患者在造血干细胞移植后更可能出现较低的肺活量值。接受强度降低的预处理或氟达拉滨加全身照射的非清髓性预处理的患者更可能在造血干细胞移植后出现更高的 FEV、FVC 和 D。
FEV、FVC 或 D 的绝对下降≥20%与生存率降低相关,与移植前的肺功能或复发状态无关。与先前的研究不同,PFT 测量的早期下降与未来闭塞性细支气管炎综合征的发展无关。